Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis

doi:10.3748/wjg.v29.i6.967

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7873)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

415

WORD

HTML

5538

Figures (1-2)

541

Sum=6549

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

175

Download

341

Sum=516

Publishing Process of This Article

Item

Count

Browse

168

Download

476

Sum=644

Feb 14, 2023 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Feb 14, 2023; 29(6): 967-996
Published online Feb 14, 2023. doi: 10.3748/wjg.v29.i6.967

Full Size Figure Download Figure

Figure 1 Circular model of crosstalk between periodontal disease, gut microbiota, diabetes mellitus, and metabolic syndrome in the pathogenesis of nonalcoholic fatty liver disease. LPS: Lipopolysaccharide; FFA: Free fatty acids; PAMPs: Pathogen-associated molecular pattern molecules; SCFA: Short-chain fatty acids; EtOH, Ethanol.

Citation: Kuraji R, Shiba T, Dong TS, Numabe Y, Kapila YL. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. World J Gastroenterol 2023; 29(6): 967-996
URL: https://www.wjgnet.com/1007-9327/full/v29/i6/967.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i6.967